Cabozantinib potentiates CAR-NK92 activity by upregulating EGFR expression and downregulating PD-L1 on tumor cells, thereby improving immune cell infiltration and reducing immune suppression within the tumor microenvironment (122). The gene discussed is EGFR; the disease is neoplasm.